Mogrify is jumping ahead of the technologies that have propelled the stem cell field by creating a platform that bypasses intermediate steps, and opens the door to in vivo reprogramming.
Cell Mogrify Ltd. uses small molecules and transcription factors to directly convert one mature cell type to another without first reverting through a pluripotent state, allowing it to avoid the problems of induced pluripotent stem (iPS) cells.
Cell therapies derived from iPS cells can be unstable due to the immature state they take before differentiating into a new cell type, and carry a heightened cancer risk if any pluripotent cells remain in the final product.
The company’s Mogrify platform skips the pluripotent state by using algorithms to predict which direct cell conversions are possible, and to identify the recipes of reprogramming factors needed.
According to CEO Darrin Disley, Mogrify is the first to company to bypass the pluripotent state in a systematic way.
Most other methods to directly reprogram cells rely on costly and time-consuming trial and error. For sets of